Discovery of Novel Class of Histone Deacetylase Inhibitors as Anticancer Agents

Raafat El‐Awady(American Association of Colleges of Pharmacy), Taleb H. Al‐Tel(University of Sharjah)

Research Square

February 5, 2021

10.21203/rs.3.rs-154323/v1

Cited by 0

Related Papers

The impact of CBP expression in estrogen receptor-positive breast cancer

|Clinical Epigenetics|2021|37

Interplay between Epigenetics, Expression of Estrogen Receptor- α, HER2/ERBB2 and Sensitivity of Triple Negative Breast Cancer Cells to Hormonal Therapy

|Cancers|2018|32

OSU-2S/Sorafenib Synergistic Antitumor Combination against Hepatocellular Carcinoma: The Role of PKCδ/p53

|Frontiers in Pharmacology|2016|30

Design and synthesis of new energy restriction mimetic agents: Potent anti-tumor activities of hybrid motifs of aminothiazoles and coumarins

|Scientific Reports|2020|28

Effect of safranal on the response of cancer cells to topoisomerase I inhibitors: Does sequence matter?

|Frontiers in Pharmacology|2022|24